Patient Symptoms on Hemodialysis-Timing, Variability and Causes
Patient Symptoms on Hemodialysis-Timing, Variability and Causes
批准号:
9808551
负责人:
Finnian R McCausland
金额:
$8.95万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2021-08-31
关键词:
AddressAdverse effectsAdverse eventAffectBiochemistryBloodBlood PressureBostonCaliberChest PainClinicClinical TrialsCollaborationsCongestiveDataDevelopmentDialysis procedureDizzinessDyspneaEnvironmentEtiologyExhibitsFluid overloadFrequenciesFunctional disorderFutureGoalsHeadacheHealth PersonnelHemodialysisIndividualInferior vena cava structureIntervention StudiesIntervention TrialIntracellular SpaceKidney FailureKnowledgeLifeLungMaintenanceMeasuresMentored Patient-Oriented Research Career Development AwardMethodsMuscle CrampNatureOsmolalitiesOutpatientsParticipantPatient CarePatient-Focused OutcomesPatientsPerformancePlasmaPlayProceduresProspective cohortProspective cohort studyProtocols documentationQuality of lifeQuestionnairesReportingResearchRoleSeveritiesSurveysSymptomsSyndromeSystemTimeUltrafiltrationUltrasonographyUnited StatesWater MovementsWeightWorkassociated symptomclinically relevantdisabling symptomexperienceimprovedindexinginnovationinsightlife-sustaining therapymortalitypatient variabilityphysical symptompoint of careportabilitypreservationrecruitsymptomatologytherapy resistant
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
There are over 400,000 patients in the United States that are dependent on the life-preserving benefits of
maintenance hemodialysis (HD). However, debilitating physical symptoms are estimated to affect over 50% of
patients during the HD procedure, often resulting in reduced quality of life. Despite decades of experience, the
exact timing, session-to-session variability, and potential etiologies of such symptoms remain unclear. Our
prior work has suggested that rapid rates of decline in plasma osmolality may play an important role in both
blood pressure decline and symptoms (such as chest pain and headache) early in the course of HD sessions;
while others suggest that inaccurate volume assessment and higher rates of ultrafiltration may play a role later
in the HD session. To address these gaps in knowledge, in Aim 1, we propose a detailed analysis of the
timing, frequency and variability of patient symptoms in a prospective cohort of contemporary HD patients. In
Aim 2, we will leverage innovative point-of-care methods to aid in the assessment of volume status, and
determine the association of osmolality decline, ultrafiltration rate and objective volume metrics (lung
ultrasound and inferior vena cava diameter) with patient symptoms during HD. In summary, our proposals are
clinically relevant, feasible and innovative. Moreover, they will provide important preliminary data that is highly
relevant to future interventional studies and R01 applications. Building on the underlying pathophysiology and
our experience in performance of clinical trials, our proposals have the potential to improve care for patients
undergoing maintenance HD for kidney failure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
-
批准号:10600056
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2022
-
负责人:Finnian R McCausland
-
依托单位:
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
-
批准号:10446192
-
项目类别:
-
资助金额:$35.01万
-
财政年份:2022
-
负责人:Finnian R McCausland
-
依托单位:
Cardiac Complications of Hemodynamic Instability during Hemodialysis
-
批准号:9267447
-
项目类别:
-
资助金额:$19.76万
-
财政年份:2015
-
负责人:Finnian R McCausland
-
依托单位:
Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRD
-
批准号:9333355
-
项目类别:
-
资助金额:$48.3万
-
财政年份:2013
-
负责人:Finnian R McCausland
-
依托单位:
海外基金